Cyclosporine

Generic Name: Cyclosporine

Brand Names: Cequa, Gengraf, Neoral, Restasis, Sandimmune, Verkazia, Vevye, Ikervis

Drug Type: Small Molecule

Chemical Formula: C_₆₂H_₁₁₁N_₁₁O_₁₂

CAS Number: 59865-13-3

Unique Ingredient Identifier: 83HN0GTJ6D

Background: Cyclosporine is a calcineurin inhibitor known for its immunomodulatory properties that prevent organ transplant rejection and treat various inflammatory and autoimmune conditions. It is isolated from the fungus Beauveria nivea. Initially manufactured by Sandoz and approved for use by the FDA in 1983, cyclosporine is now available in various products by Novar...

Indication: Cyclosporine is approved for a variety of conditions. Firstly, it is approved for the prophylaxis of organ rejection in allogeneic kidney, liver, and heart transplants. It is also used to prevent bone marrow transplant rejection. For the above indications, cyclosporine can be used in conjunction with azathioprine and corticosteroids. Finally, cyclosporine ca...

Associated Conditions: Atopic Dermatitis, Bone Marrow Transplant Rejection, Chronic transplant rejection, Connective Tissue Disorders, Dry Eyes, Graft-versus-host Disease (GVHD), Heart Transplant Rejection, Immune Thrombocytopenia (ITP), Interstitial Cystitis, Juvenile Idiopathic Arthritis (JIA), Kidney Transplant Rejection, Liver Transplant Rejection, Lupus Nephritis, Nephrotic Syndrome, Ocular Rosacea, Rheumatoid Arthritis, Severe Ulcerative Colitis, Steroid Dependent Nephrotic Syndrome, Steroid Resistant Nephrotic Syndrome, Uveitis, Vernal Keratoconjunctivitis, Blistering disorder, Refractory Ulcerative colitis, Severe Psoriasis, Severe, active Rheumatoid arthritis, Severe, recalcitrant Plaque psoriasis, Suppressed tear production

Associated Therapies: -

Clinical Trials

Corneal Tear Film Imaging of the Cornea Before and After Restasis Therapy

Not Applicable

Conditions: Dry Eye Syndrome
Tear Film Insufficiency

Interventions: Device: Tear Film Imager
Drug: Restasis

First Posted Date: 2018-01-18

Last Posted Date: 2018-01-18

Lead Sponsor: Meir Medical Center

Target Recruit Count: 40

Registration Number: NCT03403023

Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation

Phase 2

Active, not recruiting

Conditions: Acute Myeloid Leukemia
Aggressive Non-Hodgkin Lymphoma
Diffuse Large B-Cell Lymphoma
Mantle Cell Lymphoma
Myelodysplastic/Myeloproliferative Neoplasm
Myelodysplastic Syndrome
Acute Lymphoblastic Leukemia
Chronic Lymphocytic Leukemia
Recurrent Plasma Cell Myeloma
Recurrent Small Lymphocytic Lymphoma

Interventions: Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
Drug: Cyclosporine
Drug: Cyclophosphamide
Drug: Mycophenolate Mofetil
Drug: Sirolimus

First Posted Date: 2017-08-11

Last Posted Date: 2024-07-10

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 150

Registration Number: NCT03246906

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Effect of Rituximab in Treatment of Membranoproliferative Glomerulonephritis

Phase 3

Conditions: Membranoproliferative Glomerulonephritis

Interventions: Drug: Rituximab
Drug: Cyclosporin

First Posted Date: 2017-06-08

Last Posted Date: 2017-06-16

Lead Sponsor: Assiut University

Target Recruit Count: 30

Registration Number: NCT03180723

Early Tapering of Immunosuppressive Agents to Immunomodulation to Improve Survival of AML Patients

Phase 4

Conditions: Disorder Related to Bone Marrow Transplantation
Acute Myeloid Leukemia

Interventions: Drug: routine reduction of immunosuppressive drugs(cyclosporine)
Drug: Cyclosporine

First Posted Date: 2017-05-12

Last Posted Date: 2017-05-12

Lead Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Target Recruit Count: 100

Registration Number: NCT03150134

Locations: 🇨🇳
Shanghai First People's HOSPITAL, Shanghai, Shanghai, China

211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia

Phase 1

Suspended

Conditions: Acute Lymphoblastic Leukemia
Recurrent Acute Lymphoblastic Leukemia
Chronic Myelomonocytic Leukemia
Myelodysplastic Syndrome With Excess Blasts
Recurrent Acute Myeloid Leukemia
Refractory Acute Myeloid Leukemia
Mixed Phenotype Acute Leukemia
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
Acute Myeloid Leukemia
Refractory Acute Lymphoblastic Leukemia

Interventions: Drug: Cyclosporine
Drug: Fludarabine Phosphate
Other: Laboratory Biomarker Analysis
Drug: Mycophenolate Mofetil
Procedure: Peripheral Blood Stem Cell Transplantation
Other: Pharmacological Study
Radiation: Pretargeted Radioimmunotherapy
Radiation: Total-Body Irradiation

First Posted Date: 2017-04-25

Last Posted Date: 2024-06-28

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 75

Registration Number: NCT03128034

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Drug Interaction Study of Apixaban With Cyclosporine and Tacrolimus

Phase 1

Completed

Conditions: Healthy
Pharmacokinetics
Venous Thromboembolism

Interventions: Drug: Apixaban alone
Drug: Tacrolimus
Drug: Cyclosporine
Drug: Apixaban

First Posted Date: 2017-03-20

Last Posted Date: 2017-10-11

Lead Sponsor: Thomas Jefferson University

Target Recruit Count: 12

Registration Number: NCT03083782

Locations: 🇺🇸
Thomas Jefferson University, Philadelphia, Pennsylvania, United States

Alitretinoin vs Cyclosporine in Severe Recurrent Vesicular Hand Eczema

Phase 3

Conditions: Hand Eczema

Interventions: Drug: Alitretinoin
Drug: cyclosporin A

First Posted Date: 2017-01-20

Last Posted Date: 2019-02-26

Lead Sponsor: University Medical Center Groningen

Target Recruit Count: 76

Registration Number: NCT03026946

Locations: 🇳🇱
University Medical Center Groningen, Groningen, Netherlands

A Phase II Dose-escalation Study Characterizing the PK of Eltrombopag in Pediatric Patients With Previously Untreated or Relapsed Severe Aplastic Anemia or Recurrent Aplastic Anemia

Phase 2

Active, not recruiting

Conditions: Aplastic Anemia

Interventions: Drug: Eltrombopag
Drug: hATG
Drug: CsA

First Posted Date: 2017-01-19

Last Posted Date: 2024-12-06

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 51

Registration Number: NCT03025698

Locations: 🇺🇸
Aflac Cancerand Blood Disorders Ctr, Atlanta, Georgia, United States
🇺🇸
Ann and Robert H Lurie Childrens Hospital of Chicago SC, Chicago, Illinois, United States
🇺🇸
Cleveland Clinic Foundation Cleveland Clinic 5, Cleveland, Ohio, United States

and more 10 locations